Faes Farma Overview
- Year Founded
-
1933
- Status
-
Public
- Employees
-
2,611
- Stock Symbol
-
FAE
- Investments
-
11
- Share Price
-
$5.51
- (As of Tuesday Closing)
Faes Farma General Information
Description
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
Contact Information
Website
www.faesfarma.comCorporate Office
- Avenida Autonomia, 10
- 48940 Leioa
- Spain
Corporate Office
- Avenida Autonomia, 10
- 48940 Leioa
- Spain
Faes Farma Stock Performance
As of 17-Nov-2026, Faes Farma’s stock price is $5.51. Its current market cap is $1.72B with 311M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.51 | $5.60 | $4.93 - $6.41 | $1.72B | 311M | 170K | $0.32 |
Faes Farma Financials Summary
As of 30-Jun-2026, Faes Farma has a trailing 12-month revenue of $813M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,969,622 | 1,868,528 | 1,100,507 | 1,048,383 |
| Revenue | 813,297 | 688,607 | 534,175 | 488,198 |
| EBITDA | 158,852 | 133,136 | 137,029 | 131,530 |
| Net Income | 98,197 | 89,823 | 120,503 | 99,445 |
| Total Assets | 1,646,512 | 1,576,215 | 887,693 | 858,423 |
| Total Debt | 444,549 | 499,820 | 23,825 | 26,945 |
Faes Farma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Faes Farma Patents
Faes Farma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026146131-A1 | Mesalazine microparticles | Pending | 30-Dec-2024 | ||
| WO-2026146128-A1 | Vitamin d3 nanostructured lipid carriers | Pending | 30-Dec-2024 | ||
| WO-2026104388-A1 | Decongestant controlled release drug delivery system | Pending | 12-Nov-2024 | ||
| WO-2026062171-A1 | Pyridopyrimidine derivative as histamine receptor inhibitor | Pending | 20-Sep-2024 | ||
| AU-2023221541-A1 | Bilastine composition for once-daily parenteral administration | Pending | 17-Feb-2022 | A61K31/454 |
Faes Farma Signals
Faes Farma Investments & Acquisitions (11)
Faes Farma’s most recent deal was a Merger/Acquisition with SIFI for . The deal was made on 02-Sep-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SIFI | 02-Sep-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Edol | 04-Jun-2025 | Merger/Acquisition | Pharmaceuticals | ||
| NovoSci | 23-Dec-2022 | Merger/Acquisition | Distributors (Healthcare) | ||
| Global Farma | 08-Mar-2021 | Merger/Acquisition | Pharmaceuticals | ||
| BCN Medical | 30-Oct-2019 | Merger/Acquisition | Distributors (Healthcare) |
Faes Farma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.98 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Faes Farma Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Initial Technical Foods | Lanciego, Spain | 2010 | |
| Tecnologia & Vitaminas | Tarragona, Spain | 1997 | |
| Edol | Carnaxide, Portugal | 1952 | |
| SIFI | Aci Sant'Antonio, Italy | 1935 |
Faes Farma FAQs
-
When was Faes Farma founded?
Faes Farma was founded in 1933.
-
Where is Faes Farma headquartered?
Faes Farma is headquartered in Leioa, Spain.
-
What is the size of Faes Farma?
Faes Farma has 2,611 total employees.
-
What industry is Faes Farma in?
Faes Farma’s primary industry is Pharmaceuticals.
-
Is Faes Farma a private or public company?
Faes Farma is a Public company.
-
What is Faes Farma’s stock symbol?
The ticker symbol for Faes Farma is FAE.
-
What is the current stock price of Faes Farma?
As of 17-Nov-2026 the stock price of Faes Farma is $5.51.
-
What is the current market cap of Faes Farma?
The current market capitalization of Faes Farma is $1.72B.
-
What is Faes Farma’s current revenue?
The trailing twelve month revenue for Faes Farma is $813M.
-
What is Faes Farma’s annual earnings per share (EPS)?
Faes Farma’s EPS for 12 months was $0.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process